- Home
- CRVO vs MBOT Comparison
CRVO vs MBOT Comparison
Compare CRVO & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- MBOT
- Stock Information
- Founded
- CRVO 2001
- MBOT 2010
- Country
- CRVO United States
- MBOT United States
- Employees
- CRVO N/A
- MBOT N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- MBOT Medical/Dental Instruments
- Sector
- CRVO Health Care
- MBOT Health Care
- Exchange
- CRVO Nasdaq
- MBOT Nasdaq
- Market Cap
- CRVO 95.4M
- MBOT 79.2M
- IPO Year
- CRVO N/A
- MBOT N/A
- Fundamental
- Price
- CRVO $8.49
- MBOT $2.52
- Analyst Decision
- CRVO Strong Buy
- MBOT Strong Buy
- Analyst Count
- CRVO 8
- MBOT 1
- Target Price
- CRVO $25.43
- MBOT $9.00
- AVG Volume (30 Days)
- CRVO 453.1K
- MBOT 3.0M
- Earning Date
- CRVO 05-20-2025
- MBOT 05-19-2025
- Dividend Yield
- CRVO N/A
- MBOT N/A
- EPS Growth
- CRVO N/A
- MBOT N/A
- EPS
- CRVO N/A
- MBOT N/A
- Revenue
- CRVO $9,737,974.00
- MBOT N/A
- Revenue This Year
- CRVO N/A
- MBOT N/A
- Revenue Next Year
- CRVO N/A
- MBOT N/A
- P/E Ratio
- CRVO N/A
- MBOT N/A
- Revenue Growth
- CRVO 36.29
- MBOT N/A
- 52 Week Low
- CRVO $1.80
- MBOT $0.82
- 52 Week High
- CRVO $25.69
- MBOT $3.38
- Technical
- Relative Strength Index (RSI)
- CRVO 46.29
- MBOT 59.80
- Support Level
- CRVO $8.40
- MBOT $2.38
- Resistance Level
- CRVO $11.79
- MBOT $2.83
- Average True Range (ATR)
- CRVO 0.99
- MBOT 0.22
- MACD
- CRVO -0.19
- MBOT -0.02
- Stochastic Oscillator
- CRVO 10.45
- MBOT 60.76
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About MBOT Microbot Medical Inc.
Microbot Medical Inc is a clinical-stage medical device company specializing in the research, design and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. It is focused on leveraging its robotic technologies to redefine surgical robotics while improving surgical outcomes for patients. Using its LIBERTY technological platform, the company is developing the first-ever fully disposable robot for various endovascular interventional procedures.